Quarterly ResultAug 5, 2026, 08:08 AM
UroGen Q2 Revenue $72.5M; ZUSDURI Sales Up 73%; New Patent to 2044
AI Summary
UroGen Pharma reported strong second-quarter 2026 financial results, with total revenue reaching $72.5 million, significantly up from $24.2 million in Q2 2025. This growth was primarily driven by ZUSDURI, which generated $50.4 million in revenue, marking a 73% quarter-over-quarter increase. The company also announced a new U.S. patent allowance expected to protect ZUSDURI and UGN-103 until July 2044, enhancing long-term intellectual property. Additionally, UroGen is on track to submit an NDA for UGN-103 in Q3 2026 and initiate a Phase 1 trial for UGN-501 in Q4 2026, while increasing its full-year operating expense guidance.
Key Highlights
- ZUSDURI net product revenue grew 73% quarter-over-quarter to $50.4 million in Q2 2026.
- Total revenue for Q2 2026 was $72.5 million, up from $24.2 million in Q2 2025.
- New U.S. patent expected to protect ZUSDURI and UGN-103 until July 2044.
- Net loss reduced to $14.4 million ($0.28 per share) from $49.9 million ($1.05 per share) in Q2 2025.
- UGN-103 NDA submission remains on track for Q3 2026.
- JELMYTO Q2 2026 revenue was $22.0 million; 2026 guidance $97M-$101M.
- Full-year 2026 operating expense guidance increased to $260M-$270M.
- Cash, cash equivalents, and marketable securities totaled $108.0 million.
Price Impact
More from URGN